Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.

@article{Shen2010Psychedelic5M,
  title={Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.},
  author={Hong-Wu Shen and Xi-ling Jiang and Jerrold C. Winter and Ai-Ming Yu},
  journal={Current drug metabolism},
  year={2010},
  volume={11 8},
  pages={
          659-66
        }
}
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) belongs to a group of naturally-occurring psychoactive indolealkylamine drugs. It acts as a nonselective serotonin (5-HT) agonist and causes many physiological and behavioral changes. 5-MeO-DMT is O-demethylated by polymorphic cytochrome P450 2D6 (CYP2D6) to an active metabolite, bufotenine, while it is mainly inactivated through the deamination pathway mediated by monoamine oxidase A (MAO-A). 5-MeO-DMT is often used with MAO-A inhibitors such as… 

Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status

A unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed and may be further employed to predict harmaline and 5-Methoxy-N,N-dimethyltryptamine PK interactions at various doses, define the impact of CYP 2D6 status, and drive harmaline–5-Me O-D MT pharmacodynamics.

Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N , N-Dimethyltryptamine , and the Impact of CYP 2 D 6 Status

A unified PK model including the inhibition of MAO-Aand CYP2D6catalyzed 5-MeO-DMT metabolism by harmaline was developed and may be further employed to predict harmaline and 4-Methoxy-N,N-dimethyltryptamine PK interactions at various doses, define the impact of CYP1D6 status, and drive harmaline–5-Me O-D MT pharmacodynamics.

Nonlinear Pharmacokinetics of 5-Methoxy-N,N-dimethyltryptamine in Mice

A nonlinear pharmacokinetic property for 5-MeO-DMT in mice is established, suggesting that the risk of 5-Methoxy-N,N,-dimethyltryptamine intoxication may be increased nonproportionally at higher doses.

Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine

  • A. Halberstadt
  • Biology, Psychology
    Pharmacology Biochemistry and Behavior
  • 2016

Indolethylamine-N-methyltransferase Polymorphisms: Genetic and Biochemical Approaches for Study of Endogenous N,N,-dimethyltryptamine

All reported SNPs in INMT were amassed from genetic and biochemical literature and genomic databases to consolidate a blueprint for future studies aimed at elucidating whether DMT plays a physiological role.

Metabolites of Tryptamine : Endogenous psychedelic neurotransmitters , and N , N dimethyltryptamine ( DMT ) in explaining a new pathway to produce Serotonin , Melatonin and hallucinations

The journey DMT takes from the intracellular makings to the sensory faking’s renown as well as new concepts to explain the chemical pathways and their associated enzymes in the brain are highlighted.

Chapter 15 – Tryptamines

...

References

SHOWING 1-10 OF 118 REFERENCES

Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors

The ability of harmaline to modify the behavioral effects of 5-MeO-DMT is mediated by the inhibition of MAOA, and 5-HT2A receptors are responsible for the late hyperactivity induced by 5- MeO- DMT in the presence ofMAOA inhibitors.

Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats

5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens

Indolealkylamines: Biotransformations and Potential Drug–Drug Interactions

  • A. Yu
  • Biology
    The AAPS Journal
  • 2008
An important role for polymorphic cytochrome P450 2D6 (CYP2D 6) in the metabolism of IAA drugs of abuse has been revealed by recent studies, suggesting that variations in IAA metabolism, pharmaco- or toxicokinetics and dynamics can arise from distinct CYP2D6 status, and CYP1D6 polymorphism may represent an additional risk factor in the use of these IAAdrugs.

Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase.

It was ascertained that CYP2D6 does not significantly metabolize the endogenous phenylethylamine, nor the indolethylamines tryptamine, serotonin, 6-methoxytryptamine, and melatonin, norThe beta-carbolines harman, norharman and tryptoline, which are found in the brain and pineal gland.

Pharmepéna-Psychonautics: Human Intranasal, Sublingual and Oral Pharmacology of 5-Methoxy-N, N-Dimethyl-Tryptamine

  • J. Ott
  • Psychology
    Journal of psychoactive drugs
  • 2001
Abstract Summarized are psychonautic bioassays (human self-experiments) of pharmepéna—crystalline 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT; O-Me-bufotenine), at times combined with crystalline

Contribution of Individual Cytochrome P450 Isozymes to theO-Demethylation of the Psychotropic β-Carboline Alkaloids Harmaline and Harmine

Inhibition studies using monoclonal antibodies confirmed that CYP1A2 and CYP2D6 were the major isozymes contributing to both harmaline and harmine O-demethylase activities as compared with wild-type mice, and suggest a role for polymorphic CYP 2D6 in the pharmacology and toxicology of harmine and harmaline.
...